risk associated with family history of AD yielded a summary OR of 0.75 (95% CI: 0.49-1.16) based on 3 studies. There was no significant heterogeneity among studies, nor significant publication bias. Conclusions: There may be familial coaggregation of AD and PD, although the association was modest and only apparent when studying AD risk associated with family history of PD.
Introduction
Alzheimer's disease (AD) and Parkinson's disease (PD) are aging-related progressive neurodegenerative conditions affecting cognition and motor function, respectively. Although different parts of the brain are initially affected and different primary pathological protein aggregates are associated with each disease, there is widespread comorbidity of the clinical syndromes dementia and parkinsonism in conditions such as PD dementia [1] , Lewy body dementia [2] and progressive supranuclear palsy [3] . Familial aggregation has been shown for AD and PD separately, and it has been hypothesized that these diseases also coaggregate in families. The relative risk of PD associated with having a first-degree relative with PD is estimated at 2.9 (95% CI: 2.2-3.8) [4] , and the relative risk of AD associated with having a first-degree relative with AD is estimated at 3.5 (95% CI: 2.6-4.6) [5] . If familial coaggregation exists between AD and PD, shared genetic and/or familial environmental risk factors may also contribute to comorbidity of dementia and parkinsonism.
In 1991, van Duijn et al. [5] performed a meta-analysis of 2 early case-control studies [6, 7] that examined familial coaggregation of AD and PD by studying AD risk associated with family history of PD and found evidence for familial coaggregation of these diseases (pooled odds ratio, OR: 2.4; 95% CI: 1.0-5.8). Since then, an increasing number of studies have examined familial coaggregation of AD or dementia with PD or parkinsonism using both case-control and reconstructed cohort designs.
The aim of this study was to examine whether there is evidence for familial coaggregation of AD and PD and, if so, to determine the magnitude of the association between risk of AD or PD and family history of the other disease. We systematically reviewed studies published on this topic and summarized results into pooled metaestimates.
Method
We followed the MOOSE (Meta-Analysis of Observational Studies in Epidemiology) reporting guidelines [8] .
Search Strategy
We searched PubMed for peer-reviewed articles published through the end of October 2012. The following search terms were used in combination: 'Parkinson and Alzheimer' or 'Parkinson and dementia' with 'risk' or 'epidemiology' and 'family history', 'familial aggregation', 'familial risk', 'relative', 'sibling', 'twin' or 'parent'. Records found in the search were first screened for eligibility based on the title and abstract and secondly assessed for inclusion based on the full text. We also manually searched reference lists of included articles and reviews, and considered articles referred to us.
Eligibility Criteria
We considered published observational epidemiological studies that met the following criteria: (1) Study design was case-control, cohort, reconstructed cohort or cross-sectional (2) Exposure was family history of PD, parkinsonism, AD or dementia; defined as ever/never disease status among 1 or any first-degree relative (sibling, parent or offspring) (3) Outcome was disease status (incident or prevalent) of the opposite disease (e.g. if exposure was family history of PD, outcome was AD, or vice versa) (4) To be included in the quantitative analysis (meta-analysis), the studies also had to include a crude or adjusted effect estimate of association such as an OR, hazard ratio (HR)/incidence rate ratio or standardized incidence ratio (SIR), with an SE or 95% CI, or enough data allowing a crude effect estimate to be calculated, such as the number of exposed and unexposed among cases and controls in a case-control study
Data Extraction
From each study included we extracted data on: study setting, year and design (including outcome, family history exposure, comparison groups and inclusion criteria for participants); exposure and outcome ascertainment; covariates in analyses such as sex and age; numbers of study persons and events, and estimates of association with 95% CI or SE. If we were unable to identify relevant data to be extracted from the publication, we contacted the corresponding author for clarification.
Quality Assessment
We assigned a methodological quality score to all studies included, regardless of whether they fulfilled the criteria for being included in the quantitative analysis, based on 4 study characteristics. For each characteristic, the study was given a score of 1 for 'more rigorous method', or 0 for 'less rigorous method'. The scores were summed to give a total score ranging from 0 to 4. The quality characteristics were: (1) Setting: whether the study participants could be considered to be sampled in a reasonably population-based manner (1) or not (0); e.g. using neighborhood controls was considered to be a reasonably population-based manner, whereas using spouse controls, hospital-based controls or only hospital-based cases with an unspecified catchment area was not (2) Diagnostic ascertainment in first-degree relatives: whether disease status of first-degree relatives was ascertained by family history interviews only (0) or whether confirmation by clinical examination or medical record review was sought in some or all instances (1) (3) Study design: whether the study was a case-control study that did not enumerate first-degree relatives (0) or a cohort or reconstructed cohort study that did enumerate first-degree relatives (1) (4) Inclusion criteria: whether the study excluded (0) or included (1) index cases with co-occurring dementia and parkinsonism, such as in PD dementia The term 'index case' has a different meaning depending on the study design. In case-control studies of familial aggregation, the index cases are the unit of analysis along with the controls (they experience the outcome). In reconstructed cohort studies, which can be compared to matched cohort studies in design, the index cases provide the family history exposure, whereas the first-degree relatives of the index cases and controls are the unit of analysis who experience the outcome [9] .
Three investigators with experience in neuroepidemiology conducted the literature search (A.L.F. and F.Y.) and data extraction/quality assessment (A.L.F. and J.S.). The investigators were blinded to each other's findings, and disagreements were resolved by consensus decisions.
Statistical Methods
Study-specific relative risk estimates were pooled into summarized metaestimates, using the random effects model of DerSimonian and Laird [10] , and reported with 95% CI. Studies that reported the same measure of association (OR or HR/SIR) and had 71 the same outcome (AD/dementia or PD/parkinsonism) were analyzed together. For studies that reported subgroup-specific estimates but no overall estimate, we collapsed the subgroup estimates before entering them into the meta-analysis. Where possible, we calculated pooled estimates for some specific subgroups, such as first-degree relatives of young-onset index cases, sibling relationships and parent-offspring relationships. Heterogeneity among studies was evaluated with the Q-statistic from the inverse-variance fixed-effect model and with the Higgins test yielding the I 2 measure [11] . We constructed forest plots and funnel plots for each meta-analysis and assessed the presence of publication bias using Egger's test for funnel plot asymmetry [12] . Tests were twosided and the significance level was 0.05. Analyses were performed using the 'metan', 'metafunnel' and 'metabias' commands in Stata version 12.1 [13] .
Results

Studies Retrieved
The database search resulted in 405 studies that were screened for eligibility. No duplicates were found. After excluding 366 studies that were found to be ineligible based on the title and abstract, 39 remained to be assessed for inclusion. Following screening based on the full text of the remaining studies, a further 27 studies were excluded. Ultimately, 12 studies from the database search were included in the qualitative review. An additional 4 studies were identified via references and referrals, leading to a total of 16 studies included ( fig. 1 ; table 1 ).
The reasons for excluding 27 studies in the second screening are listed in online supplementary table 1 (see www.karger.com/doi/10.1159/000355452 for all online suppl. material). Briefly, 14 studies were about familial coaggregation between AD and/or PD and another outcome (such as amyotrophic lateral sclerosis, PD dementia, dementia with Lewy bodies, progressive supranuclear palsy or depression), 3 studies solely concerned the amyotrophic lateral sclerosis-PD complex of Guam, and 10 studies did not include a control group or were missing other crucial data.
Of the final 16 studies, 2 studies did not provide estimates from regression analyses but reported enough crude data that estimates could be calculated and included in the meta-analysis. Two studies fulfilled the criteria to be included in the systematic review, but they were excluded from the meta-analysis; 1 because it did not include enough relevant quantitative data [14] and 1 due to unclear results [15] . The latter study included SIR for AD risk associated with having a sibling with PD and SIR for PD risk associated with having a sibling with AD, but it was unclear from the published article which estimate
Studies included in quantitative analysis
(meta-analysis) n = 14
Studies excluded n = 366
Studies without complete quantitative data n = 2
Studies assessed for inclusion n = 39
Studies identified through references and referrals n = 4
Studies included in qualitative review n = 16
Studies identified through PubMed search, screened for eligibility n = 405
Studies excluded (see supplementary material for details) n = 27 (continued) APOE = Apolipoprotein E; C = cohort study; CC = case-control study; FDR = first-degree relatives; PDD = PD dementia; PDND = PD no dementia; RC = reconstructed cohort study.
a
The study included 1 group of cases and 2 control groups, 1 hospital based and 1 population based. Only estimates from comparisons between the cases and the population-based controls are included in the quantitative analysis. The study included a group of AD/PD cases, defined as persons with both parkinsonism and dementia. This group was treated as having both outcomes and, thus, included in quantitative analyses in both directions.
h Note that in CC studies, the index cases are the unit of analysis (experience the outcome), whereas in C/RC studies the index cases provide the family history exposure (the FDR are the unit of analysis).
i Index cases with PDD were included, but if dementia preceded PD, they were excluded. j Index cases with co-occurring dementia and parkinsonism (referred to as PDD cases in Marder et al. [18] and AD/PD cases in Rosen et al. [21] ) were included as a separate group.
was for which comparison. We were in contact with the authors of the study but did not receive sufficient information to include it. Ultimately, the meta-analyses included estimates from 14 studies.
Of the 16 studies included, 7 investigated the coaggregation of AD and PD as their primary aim [7, [16] [17] [18] [19] [20] [21] , whereas 9 studies investigated the coaggregation of AD and PD as one of many aims [6, 14, 15, [22] [23] [24] [25] [26] [27] . The relative risk estimates from the studies included in the metaanalysis could be divided into 4 groups: (1) reconstructed cohort studies estimating HR with AD or dementia as the outcome [16] [17] [18] [19] [20] (n = 5; table 2 ); (2) case-control studies estimating OR with AD or dementia as the outcome [6, 7, 21, 22, [25] [26] [27] (n = 7; table 2 ); (3) reconstructed cohort studies estimating OR with PD or parkinsonism as the outcome [23] (n = 1), and (4) case-control studies estimating OR with PD or parkinsonism as the outcome [21, 24] (n = 2). We pooled all 3 studies on PD risk associated with family history of AD, even though the study designs differed, because they all estimated OR (table 4) . Three studies included both AD and PD as outcomes [15, 19, 21] , but only 1 of these reported enough quantitative data for both outcomes to be included in their respective metaanalyses [21] . Values in parentheses denote total numbers. The pooled estimates are from random effects models. FDR = First-degree relatives; PDD = PD dementia; PDND = PD no dementia.
a The HR was collapsed from 2 estimates reported separately, 1 for FDR of PDD cases versus FDR of controls, and 1 for FDR of PDND cases versus FDR of controls.
b CI calculated from reported p values. c There is an inconsistency in the crude numbers reported in the article; an alternative interpretation is that there were 66 cases and 132 controls (there is no effect on the interpretation of the study).
d Crude OR and CI were calculated from reported frequencies as there were no adjusted estimates reported.
e The estimate included is from the reported univariate analysis (the estimate from the multivariate analysis was: OR = 4.2; 95% CI: 1.2 -15.1).
f The OR was collapsed from 2 estimates reported separately, 1 for AD cases versus controls, and 1 for AD/PD cases versus controls. 
Quality of Studies Included
The quality score assigned is listed next to each included estimate in tables 2 , 3 and 4 . Of the 16 studies included, most were assigned a score of 0-2, whereas 2 were given the highest possible quality score (4) [15, 20] (whereof 1 study [20] was included in the meta-analysis). Among the 3 studies given the second-highest possible quality score (3) [18, 19, 23] , the reason for failing to reach the highest score was a non-population-based study population in 2 studies [18, 19] , and exclusion of index cases with comorbid dementia and parkinsonism in 1 study [23] . Table 2 and figure 2 show the results of the metaanalysis of HR from 5 reconstructed cohort studies and of OR from 7 case-control studies on risk of AD or dementia associated with first-degree family history of PD. The pooled HR was 1.18 (95% CI: 1.00-1.39) and the pooled OR was 1.40 (95% CI: 0.92-2.12). One reconstructed cohort study and 2 case-control studies showed significant results in support of familial coaggregation of AD and PD, whereas the rest showed no association. Included relative risk estimates ranged from 0.9 to 4.2.
Meta-Analyses of AD Risk Associated with First-Degree Family History of PD
There was no indication of significant heterogeneity among studies.
One study [15] reported 2 estimates for coaggregation of AD and PD -SIR 10.9 (95% CI: 1.5-45.5) and SIR 8.3 (95% CI: 1.1-34.6) -but it was unclear which of the estimates was for AD as the outcome, and thus this study could not be included in the meta-analysis. As a sensitivity analysis, we pooled both SIR from this study and entered it in the meta-analysis with the reconstructed cohort studies listed in table 2 . The resulting pooled estimate was HR 1.32 (95% CI: 0.97-1.80), with p = 0.011 for heterogeneity and I 2 = 66.2%, indicating that the added study was significantly different from the other studies as there had been no indication of heterogeneity before including it. The weight of the additional study was 5.42%.
A funnel plot illustrating the relationship between study size (expressed as SE) and effect estimate in all studies of AD risk associated with family history of PD is included as online supplementary figure 1. Egger's test of funnel plot asymmetry revealed no indication of publication bias (p = 0.244). Table 3 shows the results from meta-analyses of subgroup estimates for parents/offspring, siblings and first- degree relatives of young-onset cases as well as parents/ offspring of young-onset cases from 4 reconstructed cohort studies on AD risk associated with first-degree family history of PD. Compared with the overall meta-analysis for all first-degree relatives ( table 2 ), pooled estimates were higher for parent-offspring relationships and for first-degree relatives of young-onset PD cases, although there was considerable heterogeneity among studies in both analyses. For siblings of PD cases there was no indication of an increased risk of AD in any of the 3 studies included. However, there was a strongly significant association between AD risk and family history of young-onset PD in a parent or offspring in a meta-analysis based on 2 studies. Table 4 shows the result from the meta-analysis of OR from 2 case-control studies and 1 reconstructed cohort study of PD risk associated with first-degree family history of AD. The pooled OR showed no association, with little heterogeneity among studies. Values in parentheses denote total numbers, unless specified otherwise. The pooled estimates are from random effects models. FDR = First-degree relatives; PDD = PD dementia; PDND = PD no dementia.
Meta-Analysis of PD Risk Associated with First-Degree Family History of AD
b Study-specific age cutoff for 'young onset'. 
Review of Studies Which Could Not Be Included in Meta-Analyses
Three cohort/reconstructed cohort studies investigated the PD risk associated with family history of AD but could not be included in a meta-analysis; 1 cohort study was excluded due to unclear results [15] (see above), and 2 reconstructed cohort studies were excluded as they only reported crude counts of affected first-degree relatives of cases and controls, but neither rates nor estimates of association [14, 19] . We could not include these 2 studies because the data were not suitable for calculating crude OR (as we were able to do with several case-control studies) and not enough data were reported to calculate crude HR. Mickel et al. [19] reported 5 PD events among 628 first-degree relatives of AD cases and 6 PD events among 644 first-degree relatives of spouse controls (p = 0.64 from log rank test), and Huff et al. [14] reported 1 PD event among 250 first-degree relatives of AD cases (lifetime risk: 1.0%; SD: 1.0%) and 4 PD events among 232 first-degree relatives of controls (lifetime risk: 3.9%; SD: 2.0%; p > 0.05 from test of differences in proportions).
Discussion
The finding from this systematic review is of a modest familial coaggregation between AD and PD, indicating some shared familial risk for the diseases. This conclusion is supported by several facts: (1) the only 2 studies [15, 20] that reached the highest possible quality score showed significant associations in support of familial coaggregation; (2) although pooled metaestimates from case-control and reconstructed cohort studies of AD risk associated with family history of PD were, respectively, nonsignificant and borderline significant, they were in the same direction and of similar magnitude; and (3) despite considerable variation in estimates and quality scores, there was little heterogeneity among the studies included in the main meta-analyses, which supports the validity of the results.
The quality score reflected several sources of possible bias. An example of information bias is when index cases (or their proxies) are more likely to report a family history of a disease than controls. Relying on proxy reports in studies of familial risk of PD has been shown to be prone to information bias [28] . This kind of bias may be reduced by confirming diagnoses in first-degree relatives and by enumerating all first-degree relatives, and consider each individually instead of broadly ascertaining all first-degree relatives together ('any' family history). In studies of familial coaggregation of diseases which assume a direct effect of one disease on the other within the same person (e.g. an association between PD and risk of comorbid dementia), conditioning on one of the diseases, for instance by adjusting for it in a statistical model or by stratification (exclusion of comorbid cases), may induce a biased estimate [29] . In studies of familial coaggregation of AD or dementia with PD or parkinsonism, this type of conditioning is analogous to excluding either index cases or first-degree relatives with co-occurring parkinsonism and dementia. Other types of bias include selection and ascertainment biases, which may be reduced by adhering to a population-based study design. Similar to our results, a previous meta-analysis of familial aggregation of PD showed that summary estimates from case-control stud- Values in parentheses denote total numbers. The pooled estimate is from a random effects model. a The OR was collapsed from 2 estimates reported separately, 1 for PD cases versus controls, and 1 for AD/PD cases versus controls. b Note that this is a reconstructed cohort study that reported an OR, which is why we included it in a meta-analysis among casecontrol studies. Translated to reconstructed-cohort terms, there was 1 PD case among 1,055 persons with AD family history, and 3 PD cases among 840 persons without PD family history.
ies were higher with broader CI compared with estimates from reconstructed cohort studies [4] . That study also found that non-population-based studies yielded higher estimates than population-based studies, presumably because they were more biased. Even when disregarding the quality characteristic pertaining to study design in the present review, case-control studies typically had lower quality scores than reconstructed cohort studies, which indicates that the higher summary estimate obtained from case-control studies may be more biased than that from reconstructed cohort studies.
Co-occurrence of dementia and parkinsonism is exceedingly common; the relative risk of developing dementia in PD cases compared with PD-free individuals is estimated to be between 1.7 and 5.9 [1] . It is notable that the association between dementia risk and PD appears much stronger than the association between AD risk and having a first-degree relative with PD, indicating that there must be other causes of dementia in PD besides the familial risk shared between AD and PD. Indeed, there is evidence from in vitro and in vivo studies that downstream effects from expression of risk genes for PD lead to dementia [30, 31] , and this is further supported by the observation that more advanced neuropathological stage according to Braak et al. [32] in PD is associated with cognitive decline [33] .
As this study has shown, shared familial risk for AD and PD is possibly a contributing, albeit minor, cause of the co-occurrence of parkinsonism and dementia. However, what constitutes this shared familial risk is unknown. There is little support for shared familial risk for AD and PD outside epidemiological studies. Few environmental risk factors that may be familial are known for either AD or PD, with the possible exception of the protective effect of smoking on PD [34] and the protective effect of higher education on AD [35] . Interestingly, neither of these risk factors have similar effects in AD and PD; education may even have the opposite effect in PD [36] . Furthermore, there has been no evidence of overlap between genetic risk factors for AD and PD from genome-wide scans thus far [37] [38] [39] .
One case-control study [21] and 1 reconstructed cohort study [18] used the same control group/same group of unexposed first-degree relatives in subgroup estimates, which could lead to an underestimate of the SE when pooling the subgroup estimates before entering them into the overall meta-analysis. Consequently, it could be argued that these 2 studies deserve lower weights than what was assigned to them in the random effects model. In both studies, the estimates included were closer to the null than the final pooled metaestimate, and thus the metaestimates presented in table 2 may in fact be somewhat higher than what was found, further strengthening the conclusion that there is an association between AD risk and family history of PD.
The evidence from the subgroup analyses was not consistent but still revealed some interesting findings. Based on 2 studies [16, 20] , it seems that there may be a strong association between AD risk and family history of PD for all first-degree relatives or parents/offspring of youngonset PD cases, although a third study [17] deviated from this finding. Age at onset was defined differently in each study, which makes it hard to draw firm conclusions from this finding, although it could indicate that a shared familial risk for AD and PD may share genetic causes with early-onset PD.
In the presence of familial coaggregation of AD and PD, we would generally expect the magnitude of the association to be similar regardless of which disease is the outcome and which disease the family history exposure in the study. There was no significant association between PD risk and family history of AD in any of the 3 studies included in the meta-analysis [21, 23, 24] , nor in 2 studies only included in the qualitative review [14, 19] , with the exception of the 1 study excluded from the meta-analysis due to unclear results [15] . Although the results of this systematic review and meta-analysis support a modest familial coaggregation of AD and PD, further studies of the association between PD risk and family history of AD are needed.
This study has several strengths. The comprehensive screening of retrieved studies and data extraction/quality assessment were carried out in duplicate by independent researchers. We were able to systematically study the hypothesis of familial coaggregation of AD and PD in several different epidemiological study designs. Limitations of this study are that few studies included reported separate estimates for siblings or parent-offspring relationships, making it difficult to interpret those subgroup summary findings. Among the studies included in the meta-analyses, there was only 1 study that fulfilled all 4 quality characteristics.
In conclusion, there is some evidence of familial coaggregation of AD and PD. However, the modest effect was only present when studying AD risk associated with family history of PD. Nevertheless, the familial coaggregation of AD and PD appears to be of a much smaller magnitude than the familial aggregation within each of these diseases separately, and this supports previous findings that cooccurrence of dementia and parkinsonism is primarily caused by factors other than shared familial risk.
